EA022100B1 - Способ получения лекарственного средства, содержащего тадалафил - Google Patents
Способ получения лекарственного средства, содержащего тадалафил Download PDFInfo
- Publication number
- EA022100B1 EA022100B1 EA201070046A EA201070046A EA022100B1 EA 022100 B1 EA022100 B1 EA 022100B1 EA 201070046 A EA201070046 A EA 201070046A EA 201070046 A EA201070046 A EA 201070046A EA 022100 B1 EA022100 B1 EA 022100B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- peg
- tadalafil
- drug
- solid
- polyethylene glycol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Изобретение относится к способу получения лекарственного средства, содержащего тадалафил. В указанном способе тадалафил смешивают с одним или несколькими подходящими вспомогательными веществами, выбранными из полиэтиленгликоля, моностеарата полиоксиэтиленгликоля, глицерин-полиэтиленгликоль рицинолеата, поливинилпирролидона и/или сополимера винилпирролидона с винилацетатом, и нагревают до температуры от 100 до 200°С с образованием твердого или полутвердого раствора тадалафила.
Description
(57) Изобретение относится к способу получения лекарственного средства, содержащего тадалафил. В указанном способе тадалафил смешивают с одним или несколькими подходящими вспомогательными веществами, выбранными из полиэтиленгликоля, моностеарата полиоксиэтиленгликоля, глицерин-полиэтиленгликоль рицинолеата, поливинилпирролидона и/или сополимера винилпирролидона с винилацетатом, и нагревают до температуры от 100 до 200°С с образованием твердого или полутвердого раствора тадалафила.
022100 Β1
Claims (12)
1. Способ получения лекарственного средства, содержащего тадалафил, отличающийся тем, что тадалафил смешивают с одним или несколькими подходящими вспомогательными веществами, выбранными из полиэтиленгликоля (ПЭГ), моностеарата полиоксиэтиленгликоля, глицерин-полиэтиленгликоль рицинолеата, поливинилпирролидона и/или сополимера винилпирролидона с винилацетатом и нагревают до температуры от 100 до 200°С с образованием твердого или полутвердого раствора тадалафила.
2. Способ по п.1, отличающийся тем, что температура нагревания составляет от 150 до 200°С.
3. Способ по п.2, отличающийся тем, что температура нагревания составляет 200°С.
4. Способ по любому из пп.1-3, отличающийся тем, что ПЭГ выбирают из ПЭГ-200, ПЭГ-400, ПЭГ-600, ПЭГ-800, ПЭГ-1500, ПЭГ-4000, ПЭГ-6000, ПЭГ-8000, ПЭГ-1000 и/или ПЭГ-20000, в частности из ПЭГ-400, ПЭГ-4000, ПЭГ-6000 и/или ПЭГ-20000.
5. Способ по любому из пп.1-3, отличающийся тем, что поливинилпирролидон имеет молекулярный вес приблизительно 40000, а сополимер винилпирролидона с винилацетатом имеет молекулярный вес приблизительно 60000.
6. Способ по любому из пп.1-5, отличающийся тем, что нагревание проводят в экструдере или гомогенизаторе.
7. Способ по п.6, отличающийся тем, что при экструзии в качестве вспомогательного вещества применяют поливинилпирролидон и/или сополимер винилпирролидона с винилацетатом.
8. Способ по любому из пп.1-7, отличающийся тем, что содержание тадалафила в лекарственном средстве составляет от 2 до 15 вес.%.
9. Способ по п.8, отличающийся тем, что содержание тадалафила составляет от 3 до 10 вес.%.
10. Лекарственное средство, содержащее твердый или полутвердый раствор тадалафила, которое получено способом по любому из пп.1-9.
11. Лекарственное средство по п.10, отличающееся тем, что лекарственное средство находится в форме таблетки или в форме капсулы.
12. Лекарственное средство по п.10, отличающееся тем, что 80% тадалафила высвобождается ίη νίίτο через 8-120 мин.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007028869A DE102007028869A1 (de) | 2007-06-22 | 2007-06-22 | Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil |
| PCT/EP2008/005066 WO2009000493A1 (de) | 2007-06-22 | 2008-06-23 | Verfahren zur herstellung eines arzneimittels enthaltend tadalafil |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201070046A1 EA201070046A1 (ru) | 2010-06-30 |
| EA022100B1 true EA022100B1 (ru) | 2015-11-30 |
Family
ID=39797930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201070046A EA022100B1 (ru) | 2007-06-22 | 2008-06-23 | Способ получения лекарственного средства, содержащего тадалафил |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9238007B2 (ru) |
| EP (1) | EP2170281A1 (ru) |
| JP (1) | JP5443344B2 (ru) |
| KR (1) | KR101525021B1 (ru) |
| CN (1) | CN101720221A (ru) |
| AU (1) | AU2008267431C1 (ru) |
| BR (1) | BRPI0812807A2 (ru) |
| CA (1) | CA2691667C (ru) |
| DE (1) | DE102007028869A1 (ru) |
| EA (1) | EA022100B1 (ru) |
| IL (1) | IL202783A (ru) |
| UA (1) | UA95374C2 (ru) |
| WO (1) | WO2009000493A1 (ru) |
| ZA (1) | ZA200908965B (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA028561B1 (ru) * | 2016-12-28 | 2017-11-30 | Тева Фармасьютикал Индастриз, Лтд. | Твердые лекарственные формы тадалафила |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007028869A1 (de) | 2007-06-22 | 2008-12-24 | Ratiopharm Gmbh | Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil |
| US10610528B2 (en) | 2009-12-08 | 2020-04-07 | Intelgenx Corp. | Solid oral film dosage forms and methods for making same |
| US20110136815A1 (en) | 2009-12-08 | 2011-06-09 | Horst Zerbe | Solid oral film dosage forms and methods for making same |
| US20110263606A1 (en) * | 2010-04-26 | 2011-10-27 | Horst Zerbe | Solid oral dosage forms comprising tadalafil |
| DE102010017463B4 (de) * | 2010-06-18 | 2014-02-20 | Eickhoff Antriebstechnik Gmbh | Planetenbolzen, Planetenträger, Planetengetriebe und Verfahren zur drehfesten Befestigung eines Planetenbolzens an einen Planetenträger |
| WO2012107092A1 (en) | 2011-02-10 | 2012-08-16 | Synthon Bv | Pharmaceutical composition comprising tadalafil and a cyclodextrin |
| WO2012107090A1 (en) | 2011-02-10 | 2012-08-16 | Synthon Bv | Granulated composition comprising tadalafil and a disintegrant |
| WO2012107541A1 (en) | 2011-02-10 | 2012-08-16 | Synthon Bv | Pharmaceutical composition comprising tadalafil and a cyclodextrin |
| WO2014003678A1 (en) * | 2012-06-28 | 2014-01-03 | Xspray Microparticles Ab | Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil |
| WO2014003677A1 (en) * | 2012-06-28 | 2014-01-03 | Xspray Microparticles Ab | Pharmaceutical compositions comprising solid dispersion particles containing tadalafil |
| WO2014125352A1 (en) * | 2013-02-14 | 2014-08-21 | Aurobindo Pharma Limited | Pharmaceutical compositions comprising tadalafil |
| KR102223105B1 (ko) * | 2013-04-11 | 2021-03-04 | 주식회사 씨티씨바이오 | 분산안정화제로 폴리에틸렌글리콜계 고분자 및/또는 비닐피롤리돈계 고분자를 포함하는 타다라필 유리염기 함유 필름 제형 |
| US11116769B2 (en) | 2013-04-11 | 2021-09-14 | Ctc Bio, Inc. | Tadalafil free base-containing film dosage form containing polyethylene glycol-based polymer and/or vinyl pyrrolidone-based polymer as dispersion stabilizer |
| MX2015016865A (es) * | 2013-07-05 | 2016-04-07 | Synthon Bv | Composicion farmaceutica que comprende una dispersion solida de tadalafilo. |
| WO2015000853A1 (en) * | 2013-07-05 | 2015-01-08 | Synthon B.V. | Pharmaceutical composition comprising a solid dispersion of tadalafil |
| KR101538985B1 (ko) * | 2014-09-02 | 2015-07-24 | 주식회사 서울제약 | 타다라필 구강붕해필름 및 이의 제조방법 |
| CN104523644B (zh) * | 2015-01-27 | 2017-06-20 | 江苏联环药业股份有限公司 | 一种快速溶出的氯雷他定片剂及其制备工艺 |
| KR20160138796A (ko) | 2015-05-26 | 2016-12-06 | 삼아제약 주식회사 | 타달라필을 유효성분으로 함유하는 신규한 속효성 세립제형 |
| KR101634382B1 (ko) * | 2015-10-20 | 2016-06-28 | 미래제약 주식회사 | 타다라필 경구용 액제 |
| BR112018069785A2 (pt) | 2016-03-31 | 2019-01-29 | SpecGx LLC | formas de dosagem dissuasivas de abuso de liberação prolongada |
| EP3749370A1 (de) * | 2018-02-07 | 2020-12-16 | Smawa GmbH | Pharmazeutische formulierungen, verfahren zum herstellen einer pharmazeutischen formulierung sowie ein arzneimittel umfassend eine solche |
| CN112206213A (zh) * | 2020-10-26 | 2021-01-12 | 广州汇元医药科技有限公司 | 一种枸橼酸西地那非组合物及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001008687A1 (en) * | 1999-08-03 | 2001-02-08 | Lilly Icos Llc | Beta-carboline pharmaceutical compositions |
| WO2003000343A2 (en) * | 2001-06-21 | 2003-01-03 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| US6943166B1 (en) * | 1999-04-30 | 2005-09-13 | Lilly Icos Llc. | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU171662B (hu) | 1975-07-18 | 1978-02-28 | Richter Gedeon Vegyeszet | Sposob poluchenija novykh, opticheski aktivnykh proizvodnykh apovinkaminola i ikh kislotnykh adduktov |
| CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| EP0297866A3 (en) | 1987-07-01 | 1989-12-13 | The Boots Company PLC | Therapeutic agents |
| GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| GB9423910D0 (en) | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
| GB9511220D0 (en) | 1995-06-02 | 1995-07-26 | Glaxo Group Ltd | Solid dispersions |
| GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| US6548490B1 (en) | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| US20040014761A1 (en) | 1997-10-28 | 2004-01-22 | Place Virgil A. | Treatment of female sexual dysfunction with phosphodiesterase inhibitors |
| EP1120120A4 (en) | 1998-10-05 | 2009-04-29 | Eisai R&D Man Co Ltd | TABLETS DISSOLVING DIRECTLY IN MOUTH |
| DE19918325A1 (de) | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion |
| HUP0001632A3 (en) | 1999-04-30 | 2001-12-28 | Lilly Icos Llc Wilmington | Pharmaceutical compositions comprising selective phosphodiestherase inhibitors |
| UA71629C2 (en) | 1999-08-03 | 2004-12-15 | Lilli Icos Llc | Composition containing free drug particulate form of ?-carboline (variants), method for its manufacture (variants), and method for treating sexual dysfunction |
| US6821975B1 (en) | 1999-08-03 | 2004-11-23 | Lilly Icos Llc | Beta-carboline drug products |
| ATE297196T1 (de) | 1999-12-20 | 2005-06-15 | Nicholas J Kerkhof | Verfahren zur herstellung von nanometer partikeln durch fliessbett- sprühtrocknung |
| US20030139384A1 (en) | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
| EP1269994A3 (en) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
| DK1471890T3 (da) | 2002-02-07 | 2007-01-08 | Pharmacia Corp | Farmaceutisk doseringsform til mukös afgivelse |
| US20080226723A1 (en) | 2002-07-05 | 2008-09-18 | Celonova Biosciences, Inc. | Loadable Polymeric Particles for Therapeutic Use in Erectile Dysfunction and Methods of Preparing and Using the Same |
| MXPA05001707A (es) | 2002-08-30 | 2005-04-19 | Pharmacia Corp | Formas de dosificacion farmaceutica solidas que presentan un perfil de liberacion de farmaco reproducible,. |
| US20050019641A1 (en) | 2003-06-18 | 2005-01-27 | Toshiyuki Aoyama | Fuel tank for fuel-cell and fuel cell system |
| RU2006127475A (ru) | 2003-12-29 | 2008-02-10 | Джейсон МАКДЭВИТТ (US) | Композиции и способы лечения рецидивирующих медицинских состояний |
| US20050196418A1 (en) | 2004-03-04 | 2005-09-08 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
| DE102004023069A1 (de) * | 2004-05-11 | 2005-12-08 | Bayer Healthcare Ag | Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil |
| US20060276442A1 (en) | 2004-09-08 | 2006-12-07 | Woodward John R | Methods of female sexual enhancement |
| US20060127479A1 (en) | 2004-10-08 | 2006-06-15 | Natrajan Kumaraperumal | Solvent free taste masked pharmaceutical compositions |
| US8367105B2 (en) | 2004-11-10 | 2013-02-05 | Teva Pharmaceutical Industries, Ltd. | Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby |
| MX2007010433A (es) * | 2005-02-25 | 2007-10-11 | Teva Pharma | Tadafil que tiene un tamano de particula grande y un proceso para la preparacion del mismo. |
| DE102005016981A1 (de) | 2005-04-13 | 2006-10-19 | Bayer Healthcare Ag | Kombination zur Therapie bei benigner Prostatahyperplasie |
| JP2008546786A (ja) | 2005-06-23 | 2008-12-25 | シェーリング コーポレイション | Ｐｄｅ５インヒビターの迅速吸収性経口処方物 |
| US20070009589A1 (en) | 2005-07-07 | 2007-01-11 | Kandarapu Raghupathi | Extended release compositions |
| CN1742732A (zh) * | 2005-09-20 | 2006-03-08 | 杭州恒丰医药科技有限公司 | 西力士滴丸及其制备方法 |
| JP2009542648A (ja) | 2006-07-07 | 2009-12-03 | テバ ファーマシューティカル インダストリーズ リミティド | タダラフィル及び少なくとも１種の担体を含んでなる固体組成物 |
| AU2008245597A1 (en) | 2007-04-25 | 2008-11-06 | Teva Pharmaceutical Industries Ltd. | Solid dosage forms |
| DE102007028869A1 (de) | 2007-06-22 | 2008-12-24 | Ratiopharm Gmbh | Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil |
| US20090004281A1 (en) | 2007-06-26 | 2009-01-01 | Biovail Laboratories International S.R.L. | Multiparticulate osmotic delivery system |
| US20090047330A1 (en) | 2007-08-17 | 2009-02-19 | Ramesh Bangalore | Oral fast dissolving films for erectile dysfunction bioactive agents |
| EP2240162A4 (en) | 2007-12-06 | 2013-10-09 | Bend Res Inc | NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER |
| US7957504B2 (en) | 2008-10-20 | 2011-06-07 | Los Alamos National Security, Llc | Method and apparatus for measuring enrichment of UF6 |
| DE102009033396A1 (de) | 2009-07-16 | 2011-01-20 | Ratiopharm Gmbh | Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung |
| DE102009035211A1 (de) | 2009-07-29 | 2011-02-17 | Ratiopharm Gmbh | Copräzipitate umfassend einen Phosphodiesterase-5-Inhibitor (PDE-5-Inhibitor) und einen pharmazeutisch verträglichen Trägerstoff, ihre Herstellung und Verwendung |
| CN101741732B (zh) * | 2009-11-30 | 2011-11-30 | 中国人民解放军国防科学技术大学 | 容延网络中网络节点存储器的扩展管理方法 |
-
2007
- 2007-06-22 DE DE102007028869A patent/DE102007028869A1/de not_active Withdrawn
-
2008
- 2008-06-23 UA UAA201000594A patent/UA95374C2/ru unknown
- 2008-06-23 EA EA201070046A patent/EA022100B1/ru not_active IP Right Cessation
- 2008-06-23 EP EP08759325A patent/EP2170281A1/de not_active Withdrawn
- 2008-06-23 AU AU2008267431A patent/AU2008267431C1/en not_active Ceased
- 2008-06-23 JP JP2010512607A patent/JP5443344B2/ja not_active Expired - Fee Related
- 2008-06-23 BR BRPI0812807-3A2A patent/BRPI0812807A2/pt not_active Application Discontinuation
- 2008-06-23 US US12/665,309 patent/US9238007B2/en not_active Expired - Fee Related
- 2008-06-23 WO PCT/EP2008/005066 patent/WO2009000493A1/de active Application Filing
- 2008-06-23 CA CA2691667A patent/CA2691667C/en not_active Expired - Fee Related
- 2008-06-23 KR KR1020107000944A patent/KR101525021B1/ko active IP Right Grant
- 2008-06-23 CN CN200880021058A patent/CN101720221A/zh active Pending
-
2009
- 2009-12-15 ZA ZA2009/08965A patent/ZA200908965B/en unknown
- 2009-12-17 IL IL202783A patent/IL202783A/en active IP Right Grant
-
2015
- 2015-12-16 US US14/971,141 patent/US20160101103A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6943166B1 (en) * | 1999-04-30 | 2005-09-13 | Lilly Icos Llc. | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
| WO2001008687A1 (en) * | 1999-08-03 | 2001-02-08 | Lilly Icos Llc | Beta-carboline pharmaceutical compositions |
| US6841167B1 (en) * | 1999-08-03 | 2005-01-11 | Lilly Icos Llc. | β-carboline pharmaceutical compositions |
| WO2003000343A2 (en) * | 2001-06-21 | 2003-01-03 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA028561B1 (ru) * | 2016-12-28 | 2017-11-30 | Тева Фармасьютикал Индастриз, Лтд. | Твердые лекарственные формы тадалафила |
Also Published As
| Publication number | Publication date |
|---|---|
| EA201070046A1 (ru) | 2010-06-30 |
| IL202783A (en) | 2017-01-31 |
| WO2009000493A1 (de) | 2008-12-31 |
| AU2008267431A1 (en) | 2008-12-31 |
| DE102007028869A1 (de) | 2008-12-24 |
| CA2691667C (en) | 2014-10-28 |
| US20160101103A1 (en) | 2016-04-14 |
| JP2010530858A (ja) | 2010-09-16 |
| AU2008267431B2 (en) | 2013-05-23 |
| AU2008267431C1 (en) | 2013-09-26 |
| IL202783A0 (en) | 2010-06-30 |
| ZA200908965B (en) | 2012-06-27 |
| CN101720221A (zh) | 2010-06-02 |
| JP5443344B2 (ja) | 2014-03-19 |
| KR101525021B1 (ko) | 2015-06-04 |
| EP2170281A1 (de) | 2010-04-07 |
| KR20100052453A (ko) | 2010-05-19 |
| CA2691667A1 (en) | 2008-12-31 |
| BRPI0812807A2 (pt) | 2014-12-02 |
| UA95374C2 (ru) | 2011-07-25 |
| US9238007B2 (en) | 2016-01-19 |
| US20100179159A1 (en) | 2010-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA022100B1 (ru) | Способ получения лекарственного средства, содержащего тадалафил | |
| JP7132939B2 (ja) | 新規組成物および方法 | |
| JP2014520798A5 (ru) | ||
| WO2001037896A3 (en) | Methods and compositions for administration of therapeutic reagents | |
| JP2013522308A (ja) | 凍結乾燥速溶多相剤形の製造方法 | |
| CY1118826T1 (el) | Διαδικασια για την κατασκευη ενος φαρμακευτικου σκευασματος που περιεχει glatiramer acetate | |
| DE60120710D1 (de) | Schnell zerfallende orale arzneizubereitung enthaltend valdecoxib | |
| JP2015526505A (ja) | ケタミンを含有するゲル化製剤 | |
| Lee et al. | PEGylation to improve protein stability during melt processing | |
| EA201170529A1 (ru) | Система доставки лекарственного препарата с замедленным высвобождением | |
| CN104586821B (zh) | 一种负载铂类药物的水凝胶体系及其制备方法 | |
| ES2538346T3 (es) | Procedimiento de impregnación por CO2 supercrítico | |
| EA201700426A3 (ru) | Способ производства нестерильных субстанций безводного "тамерита" и/или двухводного "галавита" - натриевых солей 5-амино-2,3-дигидрофталазин-1,4-диона (варианты) и способы дальнейшей их переработки в стерильные лекарственные препараты | |
| CN104926710B (zh) | 卡络磺钠及其制法 | |
| CY1113372T1 (el) | Μεθοδος για την κατασκευη φαρμακευτικου σκευασματος ως "παραγοντας μεταφορας" | |
| Panić et al. | The potential of natural products use in fused deposition modeling 3D printing of pharmaceutical dosage forms | |
| CN105367772B (zh) | 一种两亲性嵌段聚合物及其胶束的制备方法和应用 | |
| WO2020077045A1 (en) | Uses of modified rna encoding retinaldehyde dehydrogenase | |
| RU2323210C9 (ru) | Замещенные эфиры 1н-индол-3-карбоновой кислоты, фармацевтическая композиция, способ их получения и применения | |
| RU2791971C1 (ru) | Способ лечения и профилактики респираторных болезней подсосных поросят в групповых станках | |
| RU2684608C1 (ru) | Интерполимерный материал для медицинского и ветеринарного применения и пролонгированные лекарственные и ветеринарные средства на его основе | |
| CZ34708U1 (cs) | Kit pro test biologické účinnosti transfer faktoru | |
| RU2009127182A (ru) | Способ программируемой стимуляции репаративной регенерации в зоне шовной полосы анастомозов полых органов желудочно-кишечного тракта | |
| Wang et al. | A comprehensive review on COVID-19: What we know and how to treat against the novel coronavirus | |
| ATE450261T1 (de) | Gabapentin-zusammensetzungen zur injektion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KG MD TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): KZ RU |